| Q43174221 | 14th congress of the APSR and 3rd Joint Congress of the APSR/ACCP. |
| Q38651086 | Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors |
| Q34143347 | Advances in neuroendocrine lung tumors |
| Q55375491 | Advances on systemic treatment for lung neuroendocrine neoplasms. |
| Q46173157 | Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation |
| Q92278490 | Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma |
| Q35956791 | Arterial blood gases predict long-term prognosis in stage I non-small cell lung cancer patients |
| Q60959695 | Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer |
| Q35667603 | Bronchopulmonary carcinoid tumors. |
| Q43164130 | CUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma |
| Q28084155 | Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations |
| Q38385978 | Classification of lung neuroendocrine tumors: lights and shadows. |
| Q92631559 | Clinical Significance of Pleural Attachment and Indentation of Subsolid Nodule Lung Cancer |
| Q88709899 | Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations |
| Q52838432 | Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†. |
| Q38558296 | Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis |
| Q52609524 | Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study. |
| Q52983736 | Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. |
| Q48185600 | Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients. |
| Q30996480 | Cytologic diagnosis and differential diagnosis of lung carcinoid tumors a retrospective study of 63 cases with histologic correlation |
| Q34475613 | Deciphering squamous cell carcinoma using multidimensional genomic approaches |
| Q38557054 | Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. |
| Q60913819 | Diagnostic value of multiple tumor-associated autoantibodies in lung cancer |
| Q37472017 | EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma |
| Q34667869 | Early detection of NSCLC with scFv selected against IgM autoantibody. |
| Q47855146 | Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors |
| Q45876202 | Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience |
| Q46948530 | Lung Cancer Staging Essentials: The New TNM Staging System and Potential Imaging Pitfalls |
| Q38830349 | Lung Cancer Staging and Prognosis. |
| Q38763895 | Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual |
| Q24600394 | Lung cancer staging: clinical and radiologic perspectives |
| Q36328370 | Lung cancer: Biology and treatment options |
| Q49857572 | Lung neuroendocrine tumors: pathological characteristics |
| Q37602308 | Lung tumours with neuroendocrine differentiation |
| Q48206342 | Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system |
| Q39022545 | Molecular features and clinical outcome of lung malignancies in very young people |
| Q47226290 | Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors |
| Q55513068 | Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer. |
| Q37449019 | New TNM classification for non-small-cell lung cancer |
| Q27022737 | New TNM classification: achievements and hurdles |
| Q37874768 | Non-small-cell lung cancer. |
| Q45264604 | Novel morphological and molecular aspects of lung cancer |
| Q35972107 | Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score |
| Q35996028 | Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities |
| Q38178187 | Prognostic and predictive biomarkers in lung cancer. A review |
| Q33697964 | Prognostic factors in resected lung carcinomas |
| Q41616664 | Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group |
| Q90329797 | Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma |
| Q50196529 | Prognostic value of the frequency of vascular invasion in stage I non-small cell lung cancer |
| Q59517517 | Pulmonale Karzinoide |
| Q35854666 | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. |
| Q33593905 | Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma |
| Q51638287 | Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy. |
| Q26996521 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids |
| Q48391668 | Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses |
| Q34935037 | Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee |
| Q44553340 | Retrospective study of clinicopathological characteristics in bronchopulmonary carcinoid |
| Q42108475 | Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice |
| Q36149338 | Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids |
| Q44103167 | Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung |
| Q48206758 | Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought |
| Q37737030 | Surgical management of bronchopulmonary carcinoids: A single center experience |
| Q45758464 | Surgical treatment of low and intermediate grade lung net. |
| Q26801595 | The International Association for the Study of Lung Cancer Lymph Node Map: A Radiologic Atlas and Review |
| Q37833109 | The molecular pathogenesis and management of bronchial carcinoids |
| Q37846130 | The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers |
| Q45896572 | The role of multimodal treatment in patients with advanced lung neuroendocrine tumors |
| Q37944931 | The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer |
| Q38555848 | The seventh tumour-node-metastasis staging system for lung cancer: Sequel or prequel? |
| Q38253997 | Therapeutic biomarkers in lung neuroendocrine neoplasia. |
| Q39920340 | Updated lung cancer staging system |
| Q85750197 | [New TNM classification of lung tumors] |
| Q84972366 | [New TNM classification of malignant lung tumours] |
| Q38228596 | sGC-cGMP signaling: target for anticancer therapy |